Notice of Interim Results

Scancell Holdings Plc

23 January 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

Notice of Interim Results

Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, will announce its interim results for the six months ended 31 October 2024 on Thursday 30 January 2025.

Dr Phil L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a virtual analyst briefing at 14:00 GMT on the day of the results. There will also be a live webcast and conference call with a Q&A session, which can be accessed via this link: https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ed5646ee-d413-404a-8a95-73bfef540393.

A copy of the presentation and webcast will be shared on the Investor Relations section of the Company's website at https://scancell.co.uk/ shortly afterwards. 

-ENDS-

For further information, please contact:

Scancell Holdings plc                                                                      [phone]

Phil L'Huillier, CEO

Sath Nirmalananthan, CFO

Professor Lindy Durrant, CSO

Dr Jean-Michel Cosséry, Non-Executive Chairman

Panmure Liberum Limited (Nominated Advisor and Joint Broker)                    [phone]

Emma Earl/ Will Goode/ Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

WG Partners LLP (Joint Broker)                                                                [phone]

David Wilson/ Claes Spang/ Satheesh Nadarajah

ICR Healthcare                                                                                                 [phone]

Mary-Jane Elliott/ Angela Gray/ Lindsey Neville                                    [e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END